Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients.

Scientific reports - 19 Sept 2016

Riediger Anja Lisa, Dietz Steffen, Schirmer Uwe, Meister Michael, Heinzmann-Groth Ingrid, Schneider Marc, Muley Thomas, Thomas Michael, Sültmann Holger

Abstract excerpt

Long-lasting success in lung cancer therapy using tyrosine kinase inhibitors (TKIs) is rare since the tumors develop resistance due to the occurrence of molecularly altered subclones. The aim of this study was to monitor tumors over time based on the quantity of mutant plasma DNA and to identify early indications for therapy response and tumor progression. Serial plasma samples from lung adenocarcinoma patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Disease Progression

Share to ErbB Receptors

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 27640882
DOI: 10.1038/srep33505
PMCID: PMC5027592

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients.PMID 27640882Read ↗

Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the diseaseSemantic proximity Read ↗

Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.Semantic proximity Read ↗

Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatmentSemantic proximity Read ↗

Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment.Semantic proximity Read ↗

Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.Semantic proximity Read ↗

Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.Semantic proximity Read ↗

The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR‐TKISemantic proximity Read ↗

Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.Semantic proximity Read ↗

Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors?Semantic proximity Read ↗

Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma.Semantic proximity Read ↗

Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.